CRB 091
Alternative Names: CRB-091Latest Information Update: 16 May 2023
At a glance
- Originator Cancer Research and Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 May 2023 Cancer Research & Biotechnology intends to file Investigational New Drug (IND) application with US FDA in Q3 2024
- 04 May 2023 Cancer Research & Biotechnology plan pre-Investigational New Drug (Pre-IND) application advice meeting with US FDA in Q3 2023
- 04 May 2023 Pharmacodynamics data from a preclinical trial in cancer released by Cancer Research & Biotechnology